Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
CMPS vs LXRX — Stock Comparison
Compare CMPS and LXRX side-by-side on StoQuant: CMPS Q-Score 50 vs LXRX 46; analyst signal 80 vs 69. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- CMPS — COMPASS Pathways plc · Health Care · market cap $1.55B · Q-Score verdict Unrated (50.0) · analyst signal 80/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 91/100, valuation 74/100 · weakest signals: technicals 26/100, competitive moat 2/100. Full CMPS research.
- LXRX — Lexicon Pharmaceuticals, Inc. · Health Care · market cap $632M · Q-Score verdict Hold (46.0, grade C) · analyst signal 69/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 100/100, valuation 74/100 · weakest signals: analyst consensus 53/100, technicals 32/100. Full LXRX research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: CMPS research · LXRX research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.